• Vivani Medical (VANI) announced an agreement with Novo Nordisk to evaluate NPM-139, its semaglutide implant for chronic weight management.
  • This collaboration with a leading pharmaceutical company provides significant validation for Vivani's NanoPortalâ„¢ platform technology.
  • The company also anticipates initiating a Phase 1 clinical trial for NPM-139 in mid-2026.